Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6639945 | 0.81 | KMT2A (0.60) | KMT2ATACR3ROCK2NR1H2NR1H3 | |
| SCHEMBL2484483 | 0.77 | ROCK2 (0.58) | KMT2ATACR3ROCK2NR1H2NR1H3 | |
| SCHEMBL2484481 | 0.77 | ROCK2 (0.58) | KMT2ATACR3ROCK2NR1H2NR1H3 | |
| SCHEMBL2005987 | 0.75 | KMT2A (0.53) | KMT2ATACR3ROCK2NR1H2NR1H3 | |
| SCHEMBL14872103 | 0.74 | KMT2A (0.51) | KMT2ATACR3ROCK2NR1H2NR1H3 | |
| SCHEMBL2485143 | 0.73 | KMT2A (0.58) | KMT2AALDH1A1MEN1GAAPTGS1 | |
| SCHEMBL2488220 | 0.73 | KMT2A (0.58) | KMT2AALDH1A1MEN1GAAPTGS1 | |
| SCHEMBL28566434 | 0.73 | KMT2A (0.58) | KMT2AALDH1A1MEN1GAAPTGS1 | |
| SCHEMBL11040087 | 0.72 | MAPT (0.53) | KMT2AALDH1A1MEN1LMNA | |
| SCHEMBL1096979 | 0.71 | KMT2A (0.47) | KMT2ATACR3ROCK2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | KMT2A 4422/4885TACR3 602/4885ROCK2 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.